Trials / Unknown
UnknownNCT02008448
Endomyocardial Botulinum Toxin Injection in Patients With Persistent Atrial Fibrillation
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 160 (estimated)
- Sponsor
- Meshalkin Research Institute of Pathology of Circulation · Network
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The investigators have conducted a prospective, double-blind, randomized study to assess the comparative safety and efficacy of two different ablation strategies, PVI plus linear lesions (LL) plus botulinum toxin injection versus PVI plus linear lesions (LL), in patients with persistent or longstanding persistent AF. Results were assessed with the use of an implanted monitoring device (IMD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Pulmonary vein isolation | |
| PROCEDURE | Linear Lesion Ablation | |
| DRUG | BT injection |
Timeline
- Start date
- 2013-06-01
- Primary completion
- 2015-12-01
- Completion
- 2016-01-01
- First posted
- 2013-12-11
- Last updated
- 2015-09-23
Locations
2 sites across 2 countries: United States, Russia
Source: ClinicalTrials.gov record NCT02008448. Inclusion in this directory is not an endorsement.